SEC Form 4 · accession 0001213900-26-080869
MoonLake Immunotherapeutics · MLTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristian Reich
Officer — Chief Scientific Officer
Period of report
Jul 21, 2026
Accepted (ET)
Jul 23, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001821586
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per shareF2,F3 | Jul 21, 2026 | S | 50,000 | $20.02 | D | 2,714,746 | I | See footnote. |
| Class A ordinary shares, par value $0.0001 per shareF3 | Jul 22, 2026 | S | 2,448 | $20.00 | D | 2,712,298 | I | See footnote. |
| Class A ordinary shares, par value $0.0001 per share | holding | — | — | — | 35,389 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
- F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.